share_log

Plus Therapeutics Has Completed Of Enrollment In Cohort 2 Of The Respect-LM Phase 1/2a Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases

Plus Therapeutics Has Completed Of Enrollment In Cohort 2 Of The Respect-LM Phase 1/2a Dose Escalation Trial Of Rhenium (186Re) Obisbemeda For Leptomeningeal Metastases

Plus Therapeutics 已经完成了治疗轻度脑膜转移的 respect-lm 第 1/2a 期剂量递增试验 Rhenium (186Re) Obisbemeda 第 2 组的注册
Benzinga Real-time News ·  2023/02/01 07:14

The company said the next steps, following the Data and Safety Monitoring Board review anticipated next month, will be completing enrollment in Phase 1/Part A, followed by a meeting with the FDA to consider dose expansion in the Phase 1/Part B trial. Additionally, initial data from Phase 1/Part A is anticipated in 2H of 2023.

该公司表示,继数据与安全监测委员会预计于下个月进行审查之后,下一步将是完成第一阶段/A部分的注册,随后与FDA会面,考虑扩大1/B部分试验的剂量。此外,第一阶段/A部分的初始数据预计将在2023年下半年公布。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发